Print  |  Close

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Active: Yes
Cancer Type: Leukemia
Neuroblastoma
Sarcoma 		NCT ID: NCT06395103
Trial Phases: Phase I
Phase II 		Protocol IDs: 9999-01A (primary)
NCI-2024-04094
2023
2023-507178-41
2023-507178-41-00
jRCT2031250824
LIGHTBEAM-U01
MK-9999-01A
U1111-1295-3459
Eligibility: 6 Months - 25 Years, Male and Female Study Type: Treatment
Study Sponsor: Merck Sharp and Dohme LLC
NCI Full Details: http://clinicaltrials.gov/show/NCT06395103

Summary

Substudy 01A is part of a platform study. The purpose of this study is to assess the
efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or
refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma
(DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants
with Ewing sarcoma.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.